Apellis Pharmaceuticals announced the pricing of its initial public offering of 10,714,000 shares of common stock at a public offering price of $14 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,607,100 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Apellis. The shares are expected to begin trading on the NASDAQ Global Select Market under the ticker symbol “APLS” on Thursday, November 9, 2017. The offering is expected to close on November 13, 2017, subject to customary closing conditions.
Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering.